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Drug Dependence and Consumption
Brain
CYP regulation and expression
Drug action, toxicity, mutagenicity
Outline of the talk
CYP2A6: nicotine metabolizing (major liver)
 Genetic variation
 Down regulation by nicotine ( 30%)
CYP2B6: nicotine metabolizing (very minor liver, ? brain)
 Genetic variation
 Up regulation by nicotine and ethanol (organ specific)
CYP2E1: ethanol metabolizing (minor liver, ? brain)
 Genetic variation
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Genetically Reduced CYP2A6 
increases nicotine plasma levels





























Does slow nicotine inactivation 
reduce smoking?
Rationale:
 Dependent smokers adjust their smoking behavior to maintain nicotine levels
 Amount smoked 85% genetic 
 Risk for smoking and stopping smoking 50-70 % genetic
Xian Nic Tob Res 5(2): 245-54., 2003 Heath Behav Genet 25(2): 103-17., 1995; Heath Behav Genet 29(6): 
395-407., 1999; Koopmans Behav Genet 29(6): 383-93., 1999; Kendler Arch Gen Psychiatry 57(9): 886-92., 
2000; Carmelli N Engl J Med 327(12): 829-33., 1992; Kaprio Int J Epidemiol 11(4): 378-86., 1982; 
Koopmans JR et al, Behav Genet 29(6): 383-93., 1999
Slow Nicotine Inactivation may:
 reduce amount smoked/day – less behaviour
 reduce positive vs aversive effects
 reduce withdrawal and tolerance and neuroadaptation
Hypotheses:
Slow nicotine metabolizers
 will smoke fewer cigarettes per day
 will be less likely to be regular, dependent smokers 
 will smoke for less time, quit sooner
 respond better to NRTs
Slow metabolism decreases smoking


















































CYP2A6 slow metabolizers: 
























Caucasians “Slow” Nicotine 
metabolizers: 
 1 inactive (*2, *4) or 
 2 low activity (*9, 12) alleles
 less frequent in smokers vs 
non-smokers:  
Odds Ratio = 0.52  
( 95% CI: 0.30-0.92)
Age, sex, education, drugs
 indicates slow nicotine 


































Schoedel et al Pharmacogenetics, 14: 615, 2004
CYP2A6 slow metabolism 
























Caucasians “Slow” Nicotine 
metabolizers: 
 smoke for a shorter duration
slow nicotine inactivators are 
less likely to be current 
smokers as duration of 
smoking increases
<10   11-20   21-30   >31











Schoedel et al Pharmacogenetics, 14: 615, 2004
Pharmacogenetics of 
Treatment
Current treatment: low efficacy 
 Genetic variation in response
 Tailor medication to genetic 
make-up
 Discover novel targets for drug 
development
Genetically Slow Metabolizers have 
higher nicotine on the patch 
(treatment seeking population)

















Malaiyandi et al, 
Mol Psychiatry 2006
Genetically Slow Metabolizers have lower 
usage & equal nicotine using the spray
(treatment seeking population)

















Malaiyandi et al, 
Mol Psychiatry 2006
Smoking Cessation Rates by Nicotine 
Metabolite Ratio and Treatment












1st Qrtl 2nd Qrtl 3rd Qrtl 4th Qrtl 1st Qrtl 2nd Qrtl 3rd Qrtl 4th Qrtl
End of treatment
6-month





3-HC: Cotinine Ratio in Quartiles
n=240 n=240
Effect of ratio in TP group (p=.005); Wald Test for interaction of ratio by treatment (p=.04)
Slow Slow Fast Fast 
Male African Green Monkey
(Cercopithecus aethiops)
Methods
 Male Monkeys (n=6 per group) treated for 22 days with:
saline (s.c., BID)
nicotine (s.c., 0.3 mg/kg, BID) 
 Smoker ~ 0.5 mg/kg nicotine /day 








In vitro Nicotine metabolism is 




















































In vivo Nicotine decreases the amount 
of hepatic CYP2A6 protein and mRNA

























































Decreased CYP2A6 nicotine metabolism:
Number of Cigarettes/day
Risk to be an adult smoker
Duration Tobacco Dependence
Success of Quitting
Success on Nicotine Patch
Regulation:
Alcohol/alcoholism
no effect on activity
Nicotine/Smoking 
↓ rates of nicotine metabolism
CYP2A6 and Nicotine Metabolism
Rao et al., 2000; Xu et al., 2002; Schoedel et al. 2003 & 2004; Maliayandi et al., 2006; Lerman et al., 2006  
1946
Human CYP2B6 and Rat CYP2B1
Alters Drug and Metabolite concentrations
 Inactivate Drugs:  Nicotine (central metabolic tolerance?) 
 Activate Drugs: Bupropion (altered efficacy?)
 Endogenous Substrates: Testosterone
Genetically variable and Inducible
 Highly genetically polymorphic
 Nicotine and Ethanol induce (organ/species specific)
Cause Toxicity
 Activate drugs to toxic metabolites: Cocaine, PCP, MDMA
 Produce oxygen radicals and lipid peroxidation
Mutagenicity and Genotoxicity




 95% smokers vs 25%
 smoke more (also social drinkers) 
 are more tolerant to nicotine
 have greater tobacco withdrawal
Alcohol and Smoking
 Common genetic susceptibility (e.g. 10q24.3)
 Nicotine increases ethanol self-administration in rats and vice versa
 Synergistic increase in disease susceptibility in alcohol abusers who 
smoke
Mechanisms:
 functional tolerance (receptor adaptation)
metabolic tolerance (enzyme induction)
Gordis 1998; Le et al 2000; Lieber 1999; Benowitz et al 1999; Villard et al 1998
Smokers versus non-smokers:
 drink 2 x more ethanol 
 have faster ethanol elimination
Nicotine and ethanol selectively 














CYP in Brain: 
Unique localizations and regulation
Exquisitely sensitive to drugs, 
complex patterns of regulation 
(tissue and cell-type specific)
Functional 
(ex vivo, in vitro)
Highly localized 
(e.g., by region, cell type, membrane)
Regulated 
(e.g. organ, region, cell, membrane)
• Alter drug concentrations near receptors
• Alter endogenous functions
• Cause toxicity or mutagenicity
CYP2B6 is found in both neurons 




A. Astrocytes around a 
cerebral blood vessel in 
Frontal Cortex layer I




neurons in Frontal 
Cortex layer III 
D. Purkinje cells 
in Cerebellum 
Miksys et al Neuropharmacology 2003
Human CYP2B6 in 





Astrocytic processes stained for CYP2B6 & GFAP




CYP2B6 is higher in Cerebellar 





M – molecular layer      
P – Purkinje cell layer 
GL – granule cell layer 
Bar:  40 µm
Miksys et al Neuropharm 2003
Alcoholics and Smokers have higher 
CYP2B6 in specific brain regions
 Are the higher levels of CYP2B6 in brain due 
specifically to alcohol and nicotine?
Models
 Human neuroblastoma cell lines
 Rats treated in vivo
 Monkeys treated in vivo
Nicotine Induction of Rat 
CYP2B1 is Brain Region Specific
(1mg base/kg/day x 7 days)
OB - olfactory bulb, ST - striatum, FC - frontal cortex, OT - olfactory tubercle, 




































S Miksys et al., 2000
Biochem Pharmacol. 
Nicotine induces 
CYP2B in Frontal Cortex neurons







Nicotine increases CYP2B in 
pyramidal neurons of layers 
II-IV in rat frontal cortex 
(Bregma 2.7)
4 hr post injection
Nicotine Nicotine
7 day post injection24 hr post injection
Nicotine (1 mg/kg x 7 days) induces 
CYP2B in Piriform Cortex neurons 
(Bregma 3.2) in layer II (C, arrow) 
- Primary Antibody Saline Nicotine (1 mg/kg x 7 d)
Bar: 100 m
S Miksys et al., Biochem Pharmacol 2000. 
CYP2B1 increases in Brainstem 
with Nicotine Dose 






















































S Miksys et al., Biochem Pharmacol 2000. 
Male African Green Monkey
(Cercopithecus aethiops)
Methods
 Male Monkeys (n=6 per group) treated for 22 days with:
saline (s.c., BID)
nicotine (s.c., 0.3 mg/kg, BID) 
 Smoker ~ 0.5 mg/kg nicotine /day 
 Monkey    0.6 mg/kg nicotine/day (slightly faster metabolism)
Saline treated monkey Nicotine treated monkey
500 m 500 m
no primary 
antibody
Nicotine does not induce hepatic 
CYP2B6 in monkey liver
(same as rats and smokers)
Lee et al., Neuropharm 2006
Frontal Cortex
1.9-fold increase in CYP2B6 










Nicotine increases CYP2B6 
in monkey brain (frontal cortex)
Saline Nicotine
Lee et al., Neuropharm 2006
Nicotine induced monkey brain CYP2B6 
expression in specific cells
Frontal cortical pyramidal cells       
Caudate neuronal cells      
Dentate gyrus granular layer     
Hippocampus
CA1 region      
CA2 region      
CA3 region      








   
Thalamic ventral lateral nucleus      
All other brain regions examined did not show 
induction by nicotine
Lee et al., Neuropharm 2006
Chronic Ethanol ( gavage x 7 days) 
Increases CYP2B1 protein in rat liver



































Schoedel et al., Biochem Pharm 2001
Chronic ethanol ( i.p. x 7 days) 












































Schoedel et al., Biochem Pharm 2001
Chronic ethanol (i.p. x 7 days) increases 
Nicotine metabolism to Cotinine in rat liver
Approximately 70% of Nicotine metabolism 
is by RAT CYP2B1/2 








































Schoedel et al., Biochem Pharm 2001
Chronic Ethanol Does Not Alter 










































Schoedel et al., Biochem Pharm 2001
Nicotine Metabolizing CYP2B1
Genetics: 
CYP2B6*6 Associated with Smoking cessation
Regulation: 
Nicotine
 Liver: No effect in rat or monkey
Brain: Increases in rat and monkey brain
Liver and Brain, consistent with human data
Ethanol
Liver: Increase rat liver CYP2B1 protein, activity and mRNA
 Brain: No effect on rat brain CYP2B1
Liver consistent with human data
Brain not consistent  (species/primate or inducer?)
Miksys et al., Biochem Pharm 2000; Schoedel et al., Biochem Pharm 2001;   Miksys et al., Neuropharm 
2003;   Schoedel et al., Mol Pharm 2003;   Schoedel et al., BBA 2003; Lee et al Neuropharmacology 2006
CYP2E1
Drug Metabolism
Inactivates ethanol (metabolic tolerance)
Endogenous role - gluconeogenesis
Lieber 1999; Kunitoh et al., 1997; Albano et al 1999; LeClerq et al 2000 
Toxicity
Activates drugs (halothane, acetaminophen)
Activates procarcinogens (cigarette smoke nitrosamines)
Generates reactive oxygen species (lipoperoxidation)
Ethanol (metabolic tolerance)
Cigarette smoke, increases CYP2E1 activity
Smokers have faster alcohol elimination rates 
(tolerance/ cross-tolerance / alcohol-related disease ?)
Inducibility
Dramatic inter-ethnic variation 
in CYP2E1*1D frequencies










































Japanese        
N=128
Canadian  
Native     
Indians    
N=228






Taiwanese       
N=420
Howard et al., Pharmacogenetics 2003
Nicotine
 self-administration of alcohol in rodents
 rate of dependence on alcohol in rodents
Mechanisms:
 functional tolerance (e.g. nicotinic acetylcholine receptors)
 metabolic tolerance (increased alcohol metabolism)
Tobacco smoke 2E1 activity in rodents & humans
Tobacco, Alcohol & CYP2E1
Smokers versus non-smokers:
95% of alcoholics are smokers
smokers drink more alcohol 
higher alcohol elimination rates
Gordis 1998; Lieber 1999; Benowitz et al 1999; Kopun 1977
In vivo chlorzoxazone clearance (CYP2E1) is 
increased following smoking in humans
Benowitz 2003
Increased clearance mediated by CYP2E1?
Smoking phase
Non-smoking phase






























25% decrease in AUC 
CYP2E1 in Human Cerebellum
(Protein: Immunohistochemistry)








CYP2E1 in purkinje cells and possibly granular layer 
Howard et al., 



















Non-alcoholic          
non-smoker
No Antibody
CYP2E1 in Human Frontal Cortex
(Protein: Immunohistochemistry)
300 M 300 M300 M20 M 20 M20 M
50 M 50 M50 M
Howard et al., 






Nicotine Induces CYP2E1 in Human 
Neuronal Cell Line (IMR-32)
Howard et al., 
Br J Pharmacol 2003
Dose-dependent increase in Rat hepatic 











Saline 0.1 mg/kg 0.3 mg/kg 1.0 mg/kg
p < 0.035































Howard et al., JPET 2001
Centrilobular Induction of rat CYP2E1 






Howard et al., JPET 2001











































p < 0.001 p < 0.005
Vmax for 6OH chlorzoxazone production is increased, 
affinity (Km) unaltered
Howard et al., JPET 2001
Rat hepatic CYP2E1 is induced after 7 days by
Nicotine with a very low ED50 (0.01 mg/kg s.c.)
Tx: 0.001 - 1.0 mg/kg Nic s.c.
ST: 4 hrs post tx
Nicotine dose in mg/kg s.c.







0.001 0.01 0.1 1





























Micu et al., JPET 2003
Rat Brain Region-specific Increases of 
CYP2E1 by Alcohol and Nicotine





































Immunocytochemical data suggest basal & induced CYP2E1 predominantly glial cell expression
Howard et al., 
Br J Pharmacol 2003
Howard et al., Br J Pharmacol, 2003
Male African Green Monkey
(Cercopithecus aethiops)
Methods
 Male Monkeys (n=6 per group) treated for 22 days with:
saline (s.c., BID)
nicotine (s.c., 0.3 mg/kg, BID) 
 Smoker ~ 0.5 mg/kg nicotine /day 
 Monkey    0.6 mg/kg nicotine/day (slightly faster metabolism)
CYP2E1 is induced by Nicotine 




















Liver: Increases hepatic CYP2E1 ED50 = 0.01 mg/kg (not mRNA) 
Brain: Increases CNS CYP2E1 (not mRNA)
Consistent with human data
Ethanol
Liver: increases rat hepatic CYP2E1 (not mRNA)
Brain: increases CNS CYP2E1 (not mRNA)
Consistent with human data
Howard et al, JPET 2001;  Howard et al., Br J Pharm 2003;  Micu et al., JPET 2003;  Howard et al., Pharmacogenetics 2003; 
Schoedel & Tyndale, BBA 2003;  Joshi & Tyndale, Neuropharm 2006;   Joshi & Tyndale, DMD 2006
Know only a little about the function 
and regulation of brain CYP enzymes
Implications
Interindividual differences in drug metabolism can alter:
 Drug abuse liability
 Risk for drug dependence
 Amount of a drug consumed
 Ability to quit
 Toxicity
Enzyme Induction ( e.g. by nicotine or ethanol) can up 
and down regulate enzymes altering:
 Nicotine and ethanol metabolism (and other drugs)
 Pharmacological actions: drug effect, drug taking 
 Metabolic tolerance/ Metabolic Cross-Tolerance
 Toxicity of enzymatic pathway – contribute to disease
Effects are organ specific
And Thanks to 
The Gang
Ewa Hoffman Sharon Miksys
